Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.
Histone acetyl transferases and histone deacetylases (HDACs) are counteracting epigenetic enzymes regulating the turnover of histone acetylation thereby regulating transcriptional events in a precise manner. Deregulation of histone acetylation caused by aberrant expression of HDACs plays a key role in tumour onset and progression making these enzymes as candidate targets for anticancer drugs and therapy. Small-molecules namely histone deacetylase inhibitors (HDACi) modulating the biological function of HDACs have shown multiple biological effects including differentiation, cell cycle arrest and apoptosis in tumour models. HDACi in general have been described in plethora of reviews with respect to various cancers. However, no review article is available describing thoroughly the role of inhibitor givinostat (ITF2357 or [6-(diethylaminomethyl) naphthalen-2-yl] methyl N-[4-(hydroxycarbamoyl) phenyl] carbamate) in haematological malignancies. Thus, the present review explores the intricate role of novel inhibitor givinostat in the defined malignancies including multiple myeloma, acute myelogenous leukaemia, Hodgkin's and non-Hodgkin's lymphoma apart from myeloproliferative neoplasms. The distinct molecular mechanisms triggered by this small-molecule inhibitor in these cancers to exert cytotoxic effect have also been dealt with. The article also highlights the combination strategy that can be used for enhancing the therapeutic efficiency of this inhibitor in the upcoming future.
a Plant Virology and Molecular Pathology Laboratory, Division of Plant Pathology , SKUAST-Kashmir , Srinagar , India.
Shabir Ahmad
SA
Ganai
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002219:Carbamates / Q000737:chemistry / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D056572:Histone Deacetylase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D009196:Myeloproliferative Disorders / Q000188:drug therapy
D000970:Antineoplastic Agents; D002219:Carbamates; D056572:Histone Deacetylase Inhibitors; C575255:givinostat
Acute myelogenous leukaemia; Givinostat; Histone deacetylase inhibitors; Histone deacetylases; Hodgkin’s lymphoma; Multiple myeloma; Non-Hodgkin’s lymphoma